Concepedia

Author

Jeffrey J. Kooijman

Center for Translational Molecular MedicineORCID

Also Known As

J. Kooijman, J.J. Kooijman, Jeffrey J Kooijman, Jeffrey J. Kooijman, Jeffrey Kooijman, Kooijman, Jeffrey, Kooijman, Jeffrey J.

77

Publications

194

Citations

7

H-Index

11

Concepts

All Affiliations

Center for Translational Molecular Medicine
JJ

About

Jeffrey J. Kooijman is an author at Center for Translational Molecular Medicine specializing in cancer research, molecular oncology, and tumor biology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Health Sciences

1

1

37

2

Medicine

1

1

37

3

Cell Biology

1

1

37

4

Molecular Biology

1

1

37

5

Cancer Cell Biology

1

1

37

Jeffrey J. Kooijman

×

7

Publications

191

Citations

7

H-Index

YearCitations

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors

Neil T. Conlon, Jeffrey J. Kooijman, Suzanne J.C. van Gerwen,

British Journal of Cancer

2021

68

Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell lines

Gisele Nishiguchi, Lauren G. Mascibroda, Sarah M. Young,

Nature Communications

2024

37

Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017

Joost C.M. Uitdehaag, Jeffrey J. Kooijman, Jeroen A.D.M. de Roos,

Molecular Cancer Therapeutics

2018

27

Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020

Jeffrey J. Kooijman, Wilhelmina E. van Riel, Jelle Dylus,

Frontiers in Oncology

2022

20

Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors

Joost C.M. Uitdehaag, Jeroen A.D.M. de Roos, Martine B.W. Prinsen,

Molecular Cancer Therapeutics

2016

18

Multi-omics analyses of MEN1 missense mutations identify disruption of menin–MLL and menin–JunD interactions as critical requirements for molecular pathogenicity

Koen M.A. Dreijerink, Ezgi Ozyerli‐Goknar, Stefanie Koidl,

Epigenetics & Chromatin

2022

11

Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor

Seong Jang, Bill Strickland, Lynda Finis,

Cancer Chemotherapy and Pharmacology

2023

10

Page 1